New hope for blood cancer patients when standard treatments fail

This study is testing whether combining two drugs—canakinumab and darbepoetin alfa—can help patients with lower-risk myelodysplastic syndromes (MDS) who no longer respond to standard anemia treatments. The trial will first determine the safest dose and then see if the combination reduces the need for blood transfusions and improves blood counts. It's for patients who require frequent blood transfusions or have very low hemoglobin levels despite previous treatment.